Opus Genetics, Inc. (IRD)

Opus Genetics Statistics

Total Valuation

Opus Genetics has a market cap or net worth of $118.53 million. The enterprise value is $87.71 million.

Market Cap	118.53M
Enterprise Value	87.71M

Important Dates

The last earnings date was Wednesday, November 12, 2025, before market open.

Earnings Date	Nov 12, 2025
Ex-Dividend Date	n/a

Share Statistics

Opus Genetics has 63.05 million shares outstanding. The number of shares has increased by 99.66% in one year.

Current Share Class	63.05M
Shares Outstanding	63.05M
Shares Change (YoY)	+99.66%
Shares Change (QoQ)	+11.46%
Owned by Insiders (%)	15.97%
Owned by Institutions (%)	31.49%
Float	28.61M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	6.38
Forward PS	5.55
PB Ratio	20.34
P/TBV Ratio	19.86
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	5.99
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.23

Current Ratio	1.23
Quick Ratio	1.21
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-26.46

Financial Efficiency

Return on equity (ROE) is -338.75% and return on invested capital (ROIC) is -115.40%.

Return on Equity (ROE)	-338.75%
Return on Assets (ROA)	-60.73%
Return on Invested Capital (ROIC)	-115.40%
Return on Capital Employed (ROCE)	-528.43%
Revenue Per Employee	$812,944
Profits Per Employee	-$3.79M
Employee Count	18
Asset Turnover	0.38
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +74.07% in the last 52 weeks. The beta is 0.41, so Opus Genetics's price volatility has been lower than the market average.

Beta (5Y)	0.41
52-Week Price Change	+74.07%
50-Day Moving Average	1.83
200-Day Moving Average	1.23
Relative Strength Index (RSI)	45.66
Average Volume (20 Days)	545,248

Short Selling Information

The latest short interest is 499,215, so 0.79% of the outstanding shares have been sold short.

Short Interest	499,215
Short Previous Month	308,958
Short % of Shares Out	0.79%
Short % of Float	1.74%
Short Ratio (days to cover)	1.01

Income Statement

In the last 12 months, Opus Genetics had revenue of $14.63 million and -$68.20 million in losses. Loss per share was -$1.37.

Revenue	14.63M
Gross Profit	7.36M
Operating Income	-37.18M
Pretax Income	-68.20M
Net Income	-68.20M
EBITDA	-37.13M
EBIT	-37.18M
Loss Per Share	-$1.37

Balance Sheet

The company has $30.82 million in cash and n/a in debt, giving a net cash position of $30.82 million or $0.49 per share.

Cash & Cash Equivalents	30.82M
Total Debt	n/a
Net Cash	30.82M
Net Cash Per Share	$0.49
Equity (Book Value)	5.97M
Book Value Per Share	0.09
Working Capital	6.82M

Cash Flow

Operating Cash Flow	-32.86M
Capital Expenditures	n/a
Free Cash Flow	-32.86M
FCF Per Share	-$0.52

Margins

Gross Margin	50.32%
Operating Margin	-254.05%
Pretax Margin	-466.09%
Profit Margin	n/a
EBITDA Margin	-253.74%
EBIT Margin	-254.05%
FCF Margin	n/a

Dividends & Yields

Opus Genetics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-99.66%
Shareholder Yield	-99.66%
Earnings Yield	-57.54%
FCF Yield	-27.72%

Analyst Forecast

The average price target for Opus Genetics is $7.20, which is 282.98% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$7.20
Price Target Difference	282.98%
Analyst Consensus	Strong Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	31.40%
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	3